ClinicalTrials.gg
CompletedNCT04620135Updated Feb 27, 2023Results posted

Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

A Phase 3 interventional study of Netarsudil ophthalmic solution 0.02% and Ripasudil hydrochloride hydrate ophthalmic solution 0.4% in Primary Open Angle Glaucoma and Ocular Hypertension, sponsored by Aerie Pharmaceuticals. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-02-27.

Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.

Enrollment
6th of 17
245 · median 85
Started
2020
with 1 other
Phase 3
5 of 17
none open now
Registered
12th of 17
by date
Lead sponsor
11 of 17
Aerie Pharmaceuticals

Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 6th largest by enrollment, is one of 2 that started in 2020, is one of 5 in phase 3, and was the 12th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About netarsudil

netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing netarsudil in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

A Phase 3 Study Comparing the Efficacy and Safety of Netarsudil Ophthalmic Solution 0.02% QD to Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% BID, for Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Over A 4-Week Period.

03

Conditions studied

  • Primary Open Angle Glaucoma
  • Ocular Hypertension

Keywords

  • Glaucoma, Primary Open-Angle Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 20 years of age or older
  • Diagnosis of POAG or OHT in both eyes (POAG in one eye and OHT in the fellow eye was acceptable)
  • Medicated intraocular pressure (IOP) ≥ 14 mmHg in at least one eye and \< 30 mmHg in both eyes at screening visit
  • For POAG eyes, unmedicated (post washout) IOP ≥ 15 mmHg and \< 35 mmHg in the study eye at 2 qualification visits (09:00 hours), 2-7 days apart. At second qualification visit IOP ≥ 15 mmHg and \< 35 mmHg at 11:00 and 16:00 hour (in the same eye).
  • For OHT eyes, unmedicated (post washout) IOP ≥ 22 mmHg and \< 35 mmHg in the study eye at 2 qualification visits (09:00 hours), 2-7 days apart. At second qualification visit IOP ≥ 22 mmHg and \< 35 mmHg at 11:00 and 16:00 hours (in the same eye)
  • Best-corrected visual acuity (BCVA) +0.7 log MAR or better (20/100 Snellen or better or 0.20 or better in decimal unit) in each eye
  • Willingness and ability to give signed and follow study instructions

Exclusion criteria

Exclusion Criteria:

  • ocular disease
  • Retinal diseases that may progress during the study period
  • Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles
  • Previous glaucoma intraocular surgery
  • Refractive surgery in either eye
  • Ocular hyperemia score of moderate (+2) or severe (+3) at Qualification Visit #2
  • Ocular trauma
  • Ocular infection or inflammation
  • Any corneal disease that may confound assessment
  • Evidence of corneal deposits or cornea verticillata
  • Known to any component of netarsudil ophthalmic solution 0.02%, ripasudil hydrochloride hydrate ophthalmic solution 0.4%, or to topical anesthetic.
  • Mean central corneal thickness >620 um
  • Any abnormality preventing reliable Goldmann applanation tonometry of either eye (e.g. keratoconus)
  • Cannot demonstrate proper delivery of the eye drop
  • Clinically significant systemic disease
  • Participation in any study within 30 days prior to screening
  • Women of who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
245 participants (actual)

Study arms

  • Experimental
    Netarsudil ophthalmic solution 0.02% and netarsudil ophthalmic solution vehicle

    1 drop netarsudil 0.02% in the evening and 1 drop netarsudil vehicle in the morning in each eye.

    Drug: Netarsudil ophthalmic solution 0.02%

  • Active comparator
    Ripasudil hydrochloride hydrate ophthalmic solution 0.4%

    1 drop ripasudil twice daily in the morning and evening in each eye.

    Drug: Ripasudil hydrochloride hydrate ophthalmic solution 0.4%

Interventions

06

What researchers measure

Primary outcomes

  1. Intraocular Pressure (IOP)

    Comparison of both groups mean diurnal IOP at Week 4 (Day 29). IOP will be measured by Goldmann applanation tonometry and reported in millimeters mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Mean diurnal IOP was calculated as the average of 3 IOP values across 09:00, 11:00 and 16:00 time points.

    Time frame: 29 Days

Secondary outcomes

  1. IOP at Weeks 1 and 2

    Mean diurnal IOP as measured in mmHg at each post-treatment visit.

    Time frame: Day 8, Day 15

  2. Mean Change IOP From Baseline at Days 8, 15, 29

    Mean change from baseline in mean diurnal IOP as measured in mmHg at each post-treatment visit.

    Time frame: Baseline (Day 1), Days 8, 15, 29

07

Results

Posted Feb 27, 2023

Participant flow

Recruitment took place at 27 clinic sites in Japan starting on 30Nov2020 with last subject last visit on 30July2021.

Intent-to-Treat (ITT) Population
Participant flow — Intent-to-Treat (ITT) Population
MilestoneNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution VehicleRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%
Started122123
Completed118120
Not completed43
Per-Protocol (PP) Population
Participant flow — Per-Protocol (PP) Population
MilestoneNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution VehicleRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%
Started121122
Completed117119
Not completed43
Safety Population
Participant flow — Safety Population
MilestoneNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution VehicleRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%
Started122123
Completed118120
Not completed43
Study Completion
Participant flow — Study Completion
MilestoneNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution VehicleRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%
Started122123
Completed118120
Not completed43
Withdrew: Adverse event23
Withdrew: Withdrawal by subject20

Outcome measures

PrimaryIntraocular Pressure (IOP)

Comparison of both groups mean diurnal IOP at Week 4 (Day 29). IOP will be measured by Goldmann applanation tonometry and reported in millimeters mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Mean diurnal IOP was calculated as the average of 3 IOP values across 09:00, 11:00 and 16:00 time points.

Time frame:
29 Days
Reported as:
Least squares mean · mmHg
Intraocular Pressure (IOP)
mmHgNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution VehicleRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%
Intraocular Pressure (IOP)15.96 ± 0.15717.71 ± 0.155
Statistical analysis
  • Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle vs Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% · ANCOVA · p = <0.00001 (Analyzed as ANCOVA with mean diurnal IOP at Week 4 as the response, baseline mean diurnal IOP as a covariate, and treatment as a main effect, using the ITT population with MCMC and regression-based multiple imputation to impute missing data.) · The least squares (ls) mean difference: -1.74 · 95% CI -2.17 to -1.31
SecondaryIOP at Weeks 1 and 2

Mean diurnal IOP as measured in mmHg at each post-treatment visit.

Time frame:
Day 8, Day 15
Reported as:
Mean · mmHg
IOP at Weeks 1 and 2
mmHgNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution VehicleRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%
Mean diurnal IOP at Weeks 1 (Days 8)16.28 ± 0.14317.87 ± 0.141
Mean diurnal IOP at Weeks 2 (Days 15)16.02 ± 0.16817.83 ± 0.166
SecondaryMean Change IOP From Baseline at Days 8, 15, 29

Mean change from baseline in mean diurnal IOP as measured in mmHg at each post-treatment visit.

Time frame:
Baseline (Day 1), Days 8, 15, 29
Reported as:
Mean · mmHg
Mean Change IOP From Baseline at Days 8, 15, 29
mmHgNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution VehicleRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%
Baseline IOP mean diurnal IOP20.475 ± 0.251020.830 ± 0.3198
V4: Week 1 (Day 8) Change from Baseline-4.341 ± 0.1603-2.814 ± 0.1397
V5: Week 2 (Day 15) Change from Baseline-4.601 ± 0.1728-2.852 ± 0.1759
V6: Week 4 (Day 29) Change from Baseline-4.653 ± 0.1701-2.983 ± 0.1622

Adverse events

Collected over Volunteered or solicited AEs were collected from the time the subject received the first dose of study medication until Week 4 (Day 29) or study discontinuation. Unresolved AEs at the time of study exit were followed with proper medical care until the event was considered resolved or stabilized, the subject was lost to follow-up, or another resolution to the event was identified.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution Vehicle0/122 (0%)0/122 (0%)73/122 (59.8%)
Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%0/123 (0%)2/123 (1.6%)82/123 (66.7%)
Most frequent serious events
Most frequent serious events
EventNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution VehicleRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%
Treatment-Emergent Serious Adverse Event (TE-SAE)General disorders0/1222/123
Infections and infestationsRespiratory, thoracic and mediastinal disorders0/1221/123
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders0/1221/123
Most frequent other events
Most frequent other events
EventNetarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution VehicleRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%
Conjunctival hyperaemiaEye disorders67/12277/123
Eye irritationEye disorders7/1227/123

Baseline characteristics

Age, Customized
Age, Customized(Participants)Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution VehicleRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%Total
Age Category — < 65 years6360123
Age Category — >= 65 years5963122
Sex: Female, Male
Sex: Female, Male(Participants)Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution VehicleRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%Total
Female7866144
Male4457101
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution VehicleRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%Total
Count of participants——0
Study Eye Diagnosis
Study Eye Diagnosis(Participants)Netarsudil Ophthalmic Solution 0.02% and Netarsudil Ophthalmic Solution VehicleRipasudil Hydrochloride Hydrate Ophthalmic Solution 0.4%Total
Ocular Hypertension323567
Primary Open Angle Glaucoma9088178
08

Study locations

1 site
  • Seijo Clinic
    Setagaya-Ku, Tokyo, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jul 2021, 7 months.

Results were first posted in Feb 2023, 1 year 7 months after primary completion.

Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 7 months is below that.

Counting every sponsor, half of 49 studies reached it within 25 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2020
First posted
Nov 6, 2020
StartActual
Nov 30, 2020
Primary completionActual
Jul 9, 2021
CompletionActual
Jul 30, 2021
Results first posted
Feb 27, 2023
Last update
Feb 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04620135
Responsible party
Sponsor
First posted
Nov 6, 2020
Start date
Nov 30, 2020
Primary completion
Jul 9, 2021
Completion
Jul 30, 2021
Results posted
Feb 27, 2023
Last update
Feb 27, 2023

Study contacts

Joella Kittrell
study director · Aerie Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion